Pioneering the development
of engineered IgM antibodies
for the treatment of cancer

antibody-solo

IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

Expert in the research and development of apoptotic pathways and antibody drug conjugates. MOUNTAIN VIEW,…

Read More...

IGM-2323: High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

Read More...

Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies

November, 2019 – PEGS Europe, Lisbon Bruce Keyt, PhD, Chief Scientific Officer IGM Biosciences, Inc.,…

Read More...

A New Era in Cancer Therapeutics: Biologic Problems and Engineering Solutions

November, 2019 – PEGS Europe, Lisbon Daniel Chen, MD, PhD, Chief Medical Officer IGM Biosciences,…

Read More...

IGM Biosciences to Present at Three Upcoming Investor Conferences

MOUNTAIN VIEW, Calif. — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on…

Read More...

IGM Biosciences Announces Third Quarter 2019 Financial Results

MOUNTAIN VIEW, Calif., Nov. 7, 2019 — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology…

Read More...